Skip to main content

Center for Vaccine Development (CVD)

CVD Overview

Life-saving immunizations are one of seven great achievements in pediatric research in the past 40 years (Cheng, Monteiro et al. 2016).

Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. The faculty and global staff includes molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists, malariologists, and biostatisticians.

Vaccines are a powerful tool to fight infectious diseases worldwide. For over 40 years, the CVD at the University of Maryland School of Medicine (UM SOM) in Baltimore, MD has worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of vaccinology from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments.

While the main research thrust of basic research at the CVD has historically focused on bacterial enteric pathogens, rotavirus, and malaria, it has also worked more broadly on bacterial diseases, parasitic diseases, viral diseases, novel delivery systems, public health, and vaccine policy.




Dr. Neuzil brings over two decades of experience in infectious diseases and vaccine science, policy, and introduction. She’s led or been involved in pivotal vaccine trials that have influenced vaccine policy worldwide. A strong advocate for translating research results into vaccine policies, she was a key driver in the many changes in the influenza policy in the United States. Internationally, her research helped shape rotavirus vaccine policy. She is an expert on influenza, rotavirus, and RSV as well as in maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings.


Harness the power of vaccines to prevent disease and save lives in the most vulnerable populations.

Studies to support meeting our mission:

  • Disease burden/epidemiology to prioritize the most needed vaccines
  • Molecular pathogenesis of disease-causing infections
  • Antigen discovery for the design of effective vaccines
  • Pre-clinical vaccine development to make vaccines that are safe and effective in humans
  • Phase I, II, III, IV vaccine trials to evaluate the safety and efficacy in humans
  • Human challenge trials to understand the infectious process and measure vaccine efficacy
  • Immune correlates of protection to understand how best to stimulate immunity
  • Vaccine policy to introduce effective vaccines into vulnerable populations
  • Train the next generation of vaccinologists

Volunteer Opportunities

Give to this Department

Connect with Us:

Kathleen Neuzil, MD, MPH
CVD Director & Deputy Director of the IGH


There was a large CVD presence at the 2017 Annual Conference on Vaccine Research (ACVR) hosted by the National Foundation for Infectious Diseases (NFID), 24-26 Apr 2017.

CVD-Mali Director, Samba Sow, MD, MS named Minister of Health for Mali, 12 Apr 2017.

The CVD was well represented at the 10th International Conference on Typhoid and Other Invasive Salmonelloses in Kampala, Uganda, 4-6 Apr 2017.

Rosangela Salerno-Goncalves (Mezghanni), PhD, Stephanie Fresnay, PhD, Myron Levine, MD, DTPH, Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Marcelo Sztein, MD were among the coauthors on “Challenge of Humans with Wild-type Salmonella Enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-associated Invariant T Cells” in Frontiers in Immunology, 2017. [In Press].

Milagritos Tapia, MD, Samba Sow, MD, MS, Sharon Tennant, PhD, and Myron Levine, MD, DTPH, Associate Dean for Global Health, Vaccinology and Infectious Diseases were among the coauthors on “Distinct Salmonella Enteritidis Lineages Associated with Enterocolitis in High-income Settings and Invasive Disease in Low-income Settings” in Nature Genetics, 2017 March 30;49(4):651.

Eileen Barry, PhD was among the coauthors on “Analysis of Shigella Flexneri Resistance, Biofilm Formation, and Transcriptional Profile in Response to Bile Salts” in Infection and Immunity, 2017 Mar 27 [Epub ahead of print].

Gaelle Noel, PhD and Marcela Pasetti, PhD were among the coauthors on “A Primary Human Macrophage-enteroid Co-culture Model to Investigate Mucosal Gut Physiology and Host-pathogen Interactions” in Scientific Reports, 2017 Mar 27;7:45270.

Archived News